14 Feb 2005 - SEQUENOM, Inc. and Iceland Genomics Corporation entered into a research collaboration to analyze SEQUENOM's proprietary panels of genetic markers associated with breast and prostate cancer in Icelandic patient samples. The results of this collaboration could provide further validation of SEQUENOM's genetic markers predisposing for breast and prostate cancer, and improve the understanding of the role of these genetic markers in disease onset, progression and therapeutic response.
SEQUENOM's proprietary genetic markers were discovered through a series of genome-wide association studies and subsequently replicated in multiple independent clinical collections. Among the markers to be studied in the Icelandic population are SNPs (single nucleotide polymorphisms) from the ICAM and the NuMA gene regions. SEQUENOM and Iceland Genomics will jointly analyze the resulting data to determine to what extent SEQUENOM's disease predisposition markers are associated with specific clinical endpoints.
"Iceland is a very exciting and rewarding place for performing genetic analysis of complex diseases such as cancer. Comprehensive clinical data combined with the participation and goodwill of Icelanders and the clinical community provides an unparalleled basis for a successful research effort," said Dana Hosseini, Iceland Genomics' Chief Executive Officer. "This agreement is part of our long term strategic effort to utilize our cancer research program to develop results that can be translated into therapeutic benefits for cancer patients."
 |
www.bionity.com/news/e/43373 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/43373 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |